Company: WHWK
Filing Date: 2025-01-31
Form Type: DEFM14A
Source: 0001193125-25-018470
Chunk: 294

Company: Whitehawk Therapeutics, Inc.
Filing Date: 2025-01-31
Form: DEFM14A
Chunk 294
---
 employees.

On August 16, 2024, our board of directors approved a plan of termination that resulted in a workforce reduction of 22 employees, representing
approximately 32% of our workforce. As of January 30, 2025, we had 39 full-time employees. None of our employees are represented by labor unions or covered by collective bargaining agreements. We consider the relationship with our employees to
be good.

- 208 -

Our human capital resources objectives include, as applicable, identifying, recruiting, retaining,
incentivizing and integrating our existing and additional employees, advisors and consultants, while being committed to a diverse and dynamic workplace. The principal purposes of our equity incentive plans are to attract, retain and reward personnel
through the granting of equity-based compensation awards in order to increase stockholder value and the success of our company by motivating such individuals to perform to the best of their abilities and achieve our objectives.

Our Corporate Information

We were originally
incorporated in the State of Delaware in November 2007 under the name “Zeta Acquisition Corp. II.” Zeta Acquisition Corp. II was a “shell” company registered under the Exchange Act with no specific business plan or purpose until
it began operating the business of Aerpio Pharmaceuticals, Inc. through a merger in March 2017. In August 2021, we effected the Reverse Merger pursuant to which a wholly owned subsidiary of ours, merged with and into Aadi Subsidiary, Inc. (formerly
Aadi Bioscience, Inc.) (“Aadi Sub”), with Aadi Sub surviving as a wholly owned subsidiary of ours. Upon the closing of the Reverse Merger, we changed our name from “Aerpio Pharmaceuticals, Inc.” to “Aadi Bioscience,
Inc.” and the name of Aadi Sub was changed from “Aadi Bioscience, Inc.” to “Aadi Subsidiary, Inc.”

Our principal executive
offices are located at 17383 Sunset Boulevard, Suite A250, Pacific Palisades, California 90272. We maintain a website at www.aadibio.com, to which we regularly post copies of our press releases as well as additional information about us.
Our filings with the Securities and Exchange Commission (the “SEC”) will be available free of charge through the website as soon as reasonably practicable after being electronically filed with or furnished to the SEC. Information contained
in our website does not constitute a part of this Annual Report on Form 10-K or